Funded Biotechnology Startups in Sweden
Among the 50 most recent Sweden biotechnology rounds shown, the largest disclosed amount is $102M by Calliditas Therapeutics on 2023-12-27, which dwarfs th…
Among the 50 most recent Sweden biotechnology rounds shown, the largest disclosed amount is $102M by Calliditas Therapeutics on 2023-12-27, which dwarfs the next-largest disclosed rounds such as SmartCella’s $54M (2024-07-08), Anocca’s $46M (2025-08-18), and OssDsign AB’s $17M (2025-06-03). The low end is also visibly uneven: the smallest disclosed amount is $20K by Fluicell on 2024-10-17, far below the general concentration of mid-sized disclosed rounds.
Two time windows stand out. Recent rounds cluster in late June–July 2024 (e.g., Fluicell $20K on 2024-10-17 is not in that window, but multiple 2024-02-01 to 2024-03-14 entries appear; and 2025-06-24 through 2025-08-18 includes multiple $580K–$46M outcomes like Qlucore $580K on 2025-06-24 and Anocca $46M on 2025-08-18). Geographically, Stockholm and Lund recur frequently across multiple dates and sizes (e.g., CubaseBio $5M on 2026-02-17 in Stockholm; Sigrid Therapeutics $5M on 2026-01-07 in Stockholm; Cantargia $3M on 2025-06-17 in Lund; Ribocure Pharmaceuticals $33M on 2025-07-02 in Mölndal), with several other city hubs appearing as smaller repeats (Gothenburg, Uppsala).
Stage reporting is dominated by rows labeled “Series Unknown” (many entries), with only a minority explicitly tagged as Seed or Series B (e.g., Gesynta Pharma Series B $27M on 2025-01-20; CubaseBio Seed $5M on 2026-02-17; UTI-lizer Seed $670K on 2023-05-17). A smaller subset is explicitly undisclosed (e.g., Episurf Medical on 2026-06-26; Ascelia Pharma on 2026-04-23; EnginZyme on 2024-09-05), and the most recent round date in the list is 2026-06-30 (Oblique Therapeutics, $1M).
Most recent rounds
50 of 6010 more funded startups
This page shows the 50 most recent rounds (back to Dec 2022). The full 60-company history for this listing is available on a paid plan.
Unlock all 60 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What stands out about round sizes in this Sweden biotech list, and is there an obvious size outlier?
Calliditas Therapeutics’ $102M on 2023-12-27 is the clear disclosed outlier; the next-largest disclosed rounds are much smaller, including SmartCella’s $54M (2024-07-08) and Anocca’s $46M (2025-08-18). At the other end, Fluicell’s $20K on 2024-10-17 is the smallest disclosed amount and sits far below the mid-range outcomes like Moleculent’s $20M (2026-04-30).
Which cities look over-represented across the most recent rounds?
Stockholm and Lund show repeated appearances across multiple dates and deal sizes, including CubaseBio $5M on 2026-02-17 (Stockholm) and Sigrid Therapeutics $5M on 2026-01-07 (Stockholm), alongside Cantargia $3M on 2025-06-17 (Lund) and Alligator Bioscience $2M on 2026-05-05 (Lund). Other hubs like Gothenburg and Uppsala recur but with less density than these two city clusters.
Are the most recent entries concentrated in a particular time window, or spread out more evenly?
The list spans from 2022-12-23 (Affibody $21M) through the most recent 2026-06-30 (Oblique Therapeutics $1M). Within that span, multiple rounds appear in the 2025 mid-year to late-year period (e.g., Qlucore $580K on 2025-06-24; Ribocure Pharmaceuticals $33M on 2025-07-02; Anocca $46M on 2025-08-18), suggesting a denser readout around mid-to-late 2025 compared with isolated singletons.
How is stage disclosure handled—do explicit stages dominate, or do “Series Unknown” and undisclosed amounts show up often?
Explicitly named stages are present but “Series Unknown” appears repeatedly across the rows, while undisclosed amounts also recur (e.g., Episurf Medical on 2026-06-26; Ascelia Pharma on 2026-04-23; EnginZyme on 2024-09-05). Named-stage examples include Gesynta Pharma Series B $27M on 2025-01-20 and CubaseBio Seed $5M on 2026-02-17, indicating stage tags exist but do not dominate the list structure.
Which disclosed rounds are worth scanning first if the goal is to find unusually large funding outcomes aside from the top outlier?
Beyond the $102M outlier (Calliditas Therapeutics on 2023-12-27), the next-largest disclosed rounds include SmartCella $54M on 2024-07-08, Anocca $46M on 2025-08-18, Vicore Pharma $46M on 2023-06-09, and Ribocure Pharmaceuticals $33M on 2025-07-02. These sit well above smaller disclosed entries such as Bio-Works $60K (2026-04-16) and Hamlet Pharma $330K (2023-04-14).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.